Table 2 Estimated comparative effectiveness of a third dose of BNT162b2 and mRNA-1273 vaccines during a period spanning Delta- and Omicron-variant predominance (20 October 2021 to 15 February 2022)

From: Comparative effectiveness of third doses of mRNA-based COVID-19 vaccines in US veterans

COVID-19 outcomes

No. of events

16-week risk no. of events/10,000 persons (95% CI)

Risk difference no. of events/10,000 persons (95% CI)

Risk ratio (95% CI)

BNT162b2

mRNA-1273

BNT162b2

mRNA-1273

BNT162b2 vs mRNA-1273

Documented infectiona

1,640

1,354

353.9 (326.7, 373.2)

308.5 (276.8, 320.9)

45.4 (19.4, 84.7)

1.15 (1.06, 1.30)

Symptomatic COVID-19

114

86

21.6 (18.3, 27.9)

17.9 (11.2, 18.3)

3.7 (2.2, 14.1)

1.21 (1.12, 2.14)

Hospitalization

126

68

27.2 (21.7, 32.7)

16.6 (10.2, 20.2)

10.6 (5.1, 19.7)

1.64 (1.27, 2.79)

ICU admission

33

19

7.5 (4.8, 10.5)

5.5 (2.6, 10.0)

2.0 (−3.1, 6.3)

1.37 (0.67, 3.14)

Death

13

9

2.9 (1.6, 5.5)

2.7 (0.6, 4.9)

0.2 (−2.2, 4.0)

1.08 (0.46, 6.39)

  1. Recipients of a third dose of the BNT162b2 vaccine were matched in a 1:1 ratio to recipients of a third dose of the mRNA-1273 vaccine according to the following variables: calendar date of third dose, calendar month of second mRNA vaccine dose, age, sex, race, urbanicity of residence, geographic location coded as categories of Veterans Integrated Services Network and number of SARS-CoV-2 tests performed in the past year.
  2. aThe number of tests for SARS-CoV-2 infection recorded during the study follow-up was 14,595 for the BNT162b2 group and 14,502 for the mRNA-1273 group.
  3. CI, confidence interval.
Back to article page